EUVIMEDEUVIMED entdecken
Crossref

Vaginal progesterone and risk of preterm birth in asymptomatic women with short cervix diagnosed after 24 weeks of gestation

Doron Kabiri, Joshua I Rosenbloom, Efrat Shekel, Tehilla Stamler-Yaacobi, Shay Porat

American Journal of Obstetrics & Gynecology MFM · 2026-08 · 8 (8) · 102012

DOI: 10.1016/j.ajogmf.2026.102012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Obstetrics & Gynecology MFM, 2026-08. Verfasst von Doron Kabiri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Israel (all authors). El…. Hauptthemen laut MEDLINE: Progesterone, Premature Birth, Cervix Uteri, Progestins. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The optimal management of asymptomatic women with a short cervix first identified after 24 weeks of gestation remains uncertain. Although vaginal progesterone is effective for preventing preterm birth when cervical shortening is detected in the mid-trimester, its role in women with incidentally detected late cervical shortening is unclear. OBJECTIVE To evaluate whether vaginal progesterone treatment is associated with a reduced risk of spontaneous preterm birth among asymptomatic women with a short cervix first identified after 24 weeks of gestation. STUDY DESIGN This retrospective cohort study included asymptomatic singleton pregnancies with a cervical length of 25 mm or less first identified between 24+0 and 33+6 weeks of gestation. Patients were categorized according to whether vaginal progesterone therapy was initiated following the diagnosis of a short cervix or whether expectant management was chosen. The primary outcome was spontaneous preterm birth before 37 weeks of gestation. Secondary outcomes included spontaneous preterm birth before 34, 32 and 28 weeks, diagnosis-to-delivery interval and selected maternal and neonatal outcomes. Time-to-delivery analyses were performed using Kaplan-Meier estimates and univariable Cox proportional hazards regression. RESULTS Among 154 asymptomatic women included in the analysis, 65 (42.2%) received vaginal progesterone and 89 (57.8%) were managed expectantly. Spontaneous preterm birth before 37 weeks occurred in 16 women (24.6%) in the progesterone group and in 17 women (19.1%) in the expectant management group (P = 0.41). Rates of spontaneous preterm birth before 34 weeks were similarly low in both groups (3.1% vs. 5.6%, P = 0.46). Kaplan-Meier analysis demonstrated no difference in time to delivery between groups (log-rank P = 0.60). In Cox proportional hazards regression, vaginal progesterone treatment was not associated with time to delivery (HR 1.28; 95% confidence interval, 0.65-2.54; P = 0.47). Women treated with progesterone had a shorter cervical length at diagnosis and a higher rate of previous preterm birth compared with those managed expectantly (17.5 ± 5.2 vs. 20.8 ± 4.2 mm, P < 0.001). Multivariable logistic regression analysis similarly demonstrated no independent association between vaginal progesterone treatment and preterm birth (aOR 0.89, 95% CI 0.38-2.13). Maternal and neonatal outcomes were similar between the groups. These findings remained consistent across time-to-event analysis and multivariable adjustment for baseline differences. CONCLUSIONS In asymptomatic women with a short cervix first identified after 24 weeks of gestation, vaginal progesterone therapy was not associated with a reduction in spontaneous preterm birth. CONDENSATION In asymptomatic women with a short cervix first diagnosed after 24 weeks of gestation, vaginal progesterone treatment was not associated with a reduction in spontaneous preterm birth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgesteronePremature BirthCervix UteriProgestinsHumansFemalePregnancyRetrospective StudiesAdministration, IntravaginalAdultCervical Length MeasurementPregnancy Trimester, SecondGestational AgeProportional Hazards Models

Stichwörter der Autor:innen

admission to neonatal intensive care unitpregnancyprematuritypreterm deliverypreterm laborprogesteroneprogestogenshort cervixtransvaginal ultrasound

Substanzen

ProgesteroneProgestins

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Israel (all authors). Electronic address: doronkabiri@gmail.com.
  • Department of Obstetrics and Gynecology, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Israel (all authors).

Zitieren

APA

Kabiri, D., Rosenbloom, J. I., Shekel, E., Stamler-Yaacobi, T., & Porat, S. (2026). Vaginal progesterone and risk of preterm birth in asymptomatic women with short cervix diagnosed after 24 weeks of gestation. American Journal of Obstetrics & Gynecology MFM, 8(8), 102012. https://doi.org/10.1016/j.ajogmf.2026.102012

Vancouver

Kabiri D, Rosenbloom JI, Shekel E, Stamler-Yaacobi T, Porat S. Vaginal progesterone and risk of preterm birth in asymptomatic women with short cervix diagnosed after 24 weeks of gestation. American Journal of Obstetrics & Gynecology MFM. 2026;8(8):102012. doi:10.1016/j.ajogmf.2026.102012

BibTeX
@article{Kabiri2026,
  author = {Kabiri, Doron and Rosenbloom, Joshua I and Shekel, Efrat and Stamler-Yaacobi, Tehilla and Porat, Shay},
  title = {Vaginal progesterone and risk of preterm birth in asymptomatic women with short cervix diagnosed after 24 weeks of gestation},
  journal = {American Journal of Obstetrics & Gynecology MFM},
  year = {2026},
  volume = {8},
  number = {8},
  pages = {102012},
  doi = {10.1016/j.ajogmf.2026.102012}
}
Kostenlos starten →